Cardiovascular
5 Early-Stage Cardiovascular Startups Changing Heart Care
DealBio tracks early-stage cardiovascular startups across Europe and North America. These 5 span prevention, home monitoring, minimally invasive repair and heart-muscle regeneration.
- Medtech
- Digital Health
- Preventive Health
- Heart Failure
Cardiovascular innovation is extending across more of the care pathway, from earlier risk detection and home monitoring to minimally invasive repair and heart-muscle regeneration.
These five startups address different points along that pathway, using software, wearables, implantable devices and regenerative therapies.
At a Glance
- AortexGermany2024Patient-specific aortic stent grafts
- Ibnova TherapeuticsDenmark2026Vascularized heart muscle replacement
- OneCareAISpain2024Electrocardiogram-based stroke-risk prediction
- PrecorDxNetherlands2023Home monitoring for heart failure
- HealthNestUnited Kingdom2024Home blood-pressure management
01
Aortex
Building smaller, patient-specific stent grafts for minimally invasive aortic repair.
- Country
Germany- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why Aortex stands out
Aortex is developing smaller, patient-specific stent grafts to widen access to minimally invasive aortic repair. It has signed letters of intent, built a working prototype and filed a patent application whose novelty has been confirmed.
The design targets patients whose access vessels are too small or whose anatomy is too complex for conventional devices, where open surgery may otherwise be the main option.
What Aortex is building
Aortex uses a thin membrane and automated manufacturing to produce patient-specific stent grafts from CT imaging. Its design targets catheter diameters up to 20% smaller than conventional systems.
A smaller delivery system may reach narrower vessels, while automated manufacturing is designed to shorten production time for an anatomy-matched implant.
Developing vascularized heart muscle patches to treat heart failure.
- Country
Denmark- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Ibnova Therapeutics stands out
Ibnova Therapeutics is developing vascularized heart-muscle patches based on cardiac-regeneration research with translational precedent. Engineered heart tissue from the founders’ research restored heart function in animal models, while co-founder James Hudson contributed to earlier cardiac-patch work that reached a Phase 1/2 trial.
The startup joined BioInnovation Institute Venture Lab with up to €500,000 in convertible financing and is working with the Novo Nordisk Foundation Cellerator, a facility for cell-therapy process development and scale-up, on scalable manufacturing.
What Ibnova Therapeutics is building
Ibnova Therapeutics grows vascularized human heart-muscle patches from stem cells. The patch combines cardiomyocytes with vascular cells and is designed to be attached over damaged myocardium after a heart attack.
The product is intended to be allogeneic, meaning made from donor cells for use in multiple patients, and available off the shelf. The aim is to replace lost heart muscle rather than only manage the symptoms of heart failure.
Developing AI software to estimate stroke risk from electrocardiogram (ECG) recordings.
- Country
Spain- Founded
- 2024
- Sector
- Digital health
- Funding stage
- Seed or earlier
- Founders
Why OneCareAI stands out
OneCareAI is using an existing, inexpensive cardiovascular signal as a screening input. Its technology originated at the Barcelona Supercomputing Center and has moved into hospital pilot and validation work in Spain and Italy.
More than 3,000 people registered for a government-backed wearable study, giving OneCareAI experience with cardiovascular data collection at population scale.
What OneCareAI is building
OneCareAI is building hospital software that analyzes ECG recordings alongside genetic, molecular, clinical and lifestyle data. The aim is to detect hidden cardiac patterns associated with cardioembolic stroke before a stroke occurs.
The workflow can use ECG machines, patches and compatible wearables, then surface a risk score and alert to clinicians. By working with signals already collected in cardiovascular care, OneCareAI is designed to add stroke-risk prediction to existing prevention workflows.
04
PrecorDx
Developing a wearable radio-frequency sensor for home heart-function monitoring.
- Country
Netherlands- Founded
- 2023
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why PrecorDx stands out
PrecorDx combines university-developed sensing technology with founders experienced in cardiovascular research, imaging and commercialization. Its radio-frequency method is patent-backed and has produced human-study results.
PrecorDx has received NWO Take-off and Health~Holland support and has moved into clinical pilot work. The sensing approach does not require repeated blood draws or implantable sensors.
What PrecorDx is building
PrecorDx is developing a wearable radio-frequency sensing system that tracks cardiac and respiratory motion from the chest. The goal is to detect changes associated with worsening heart failure before they become severe enough to require hospital care.
The product is designed for repeated use at home, giving clinicians a denser view of a patient’s status between visits and supporting earlier review when measurements change.
Helping people track and manage blood pressure at home with reminders and reports.
- Country
United Kingdom- Founded
- 2024
- Sector
- Consumer health
- Funding stage
- Seed or earlier
- Founders
Why HealthNest stands out
HealthNest has already launched on iOS and Android and was co-designed with more than 100 patients and clinicians. The team brings direct NHS experience, and co-founder Adam Wright was selected for the NHS Clinical Entrepreneur Programme.
HealthNest builds on an established home blood-pressure workflow. The app focuses on adherence, trend interpretation and sharing readings with clinicians.
What HealthNest is building
HealthNest helps people log blood-pressure readings, understand trends, receive reminders and generate reports they can share with clinicians. The app turns individual home readings into trends and shareable reports that can be reviewed during routine care.
HealthNest has also outlined a broader path toward connected blood-pressure and ECG monitoring and a clinician offering, moving the product toward a more integrated prevention and chronic-care workflow.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
The cardiovascular opportunity is spreading across the care pathway
These startups split between technologies that change when clinicians act and technologies that change what treatment is possible. OneCareAI, PrecorDx and HealthNest are designed to surface risk or deterioration earlier; Aortex and Ibnova Therapeutics are developing new options when anatomy or damaged heart muscle limits existing care.
That creates two distinct routes to value: better timing of existing care and new treatment options for patients not well served by current procedures or therapies.
Methodology
DealBio selected these startups from its coverage of early-stage health and longevity startups, focusing on startups addressing different stages of cardiovascular care. The selection spans prevention, home monitoring, minimally invasive repair and regenerative treatment.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.